Suchitra Sundaram, MD, breaks down the wealth of data presented at ASH 2023 and provides initial impressions of several key study results centering on new and encouraging treatments for diffuse large B-cell lymphoma.
Starting with a landmark analysis of a phase 2 trial testing the efficacy of the bispecific antibody glofitamab in the relapsed/refractory setting, Dr Sundaram notes not only its effect on complete response rates but also its prognostic utility in terms of progression-free survival. Touching on other studies involving bispecific antibodies with novel agents and also a chemotherapy-free regimen, Dr Sundaram concludes by discussing a new approach to measuring circulating tumor DNA, phased variant and detection sequencing (PhasED-Seq), which promises to enhance the capacity for earlier disease detection and permit more accurate prognosis.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASH 2023: Key Insights on Advances in DLBCL - Medscape - Dec 15, 2023.
Comments